Is the use of resveratrol in the treatment and prevention of obesity premature?

Nutrition Research Reviews

Volumn 22, Issue 2, 2009, Pages 111-117

  Van Der Spuy, Wendy J ^a   Pretorius, Etheresia ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Cardiovascular disease; Inflammation; Obesity; Resveratrol

Indexed keywords

RESVERATROL; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; PHENOL DERIVATIVE; PLANT EXTRACT; STILBENE DERIVATIVE;

CALORIC RESTRICTION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; ADULT; ANIMAL; CHILD; DRUG ADMINISTRATION; INFLAMMATION; INTRAABDOMINAL FAT; KIDNEY; PATHOPHYSIOLOGY;

ANIMALIA;

ADULT; ANIMALS; ANTIOXIDANTS; CHILD; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFLAMMATION; INTRA-ABDOMINAL FAT; KIDNEY; OBESITY; PHENOLS; PLANT EXTRACTS; STILBENES;

EID: 77950347503     PISSN: 09544224     EISSN: 14752700     Source Type: Journal    
DOI: 10.1017/S0954422409990084     Document Type: Review

References (57)

1. Avogaro A & de Kreutzenberg SV (2005) Mechanisms of endothelial dysfunction in obesity. Clin Chim Acta 360, 9-26.
2. Baur JA, Pearson KJ, Price NL, et al. (2006) Resveratrol improves health and survival of mice on a high calorie diet. Nature 444, 337-342.
3. Wellman NS & Friedberg B (2002) Causes and consequences of adult obesity: health, social and economic impacts in the United States. Asia Pac J Clin Nutr 11, Suppl. 8, s705-s709.
4. Levy LZ & Petty K (2008) Childhood obesity prevention: compelling challenge of the twenty-first century. Early Child Dev Care 178, 609-615.
5. Naderali EK (2009) Obesity and cardiovascular dysfunction: a role for resveratrol? Obes Res Clin Pract 3, 45-52.
6. De Jongh RT, Serne EH, Ilserman RG, et al. (2004) Impaired microvascular function in obesity: implications for obesityassociated microangiopathy, hypertension, and insulin resistance. Circulation 109, 2529-2535.
7. Breen DM, Sanli A, Giacca A, et al. (2008) Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem Biophys Res Commun 374, 117-122.
8. Das KD & Maulik N (2006) Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interventions 6, 36-47.
9. Joe AK, Liu H, Suzui M, et al. (2002) Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 8, 893-903.
10. Palsamy P & Subramanian S (2008) Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocinnicotinamide induced experimental diabetic rats. Biomed Pharmacother 62, 598-605.
11. Virgili M & Contestabile A (2000) Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci Lett 281, 123-126.
12. Bhat KP, Kosmeder JW II & Pezzuto JM (2001) Biological effects of resveratrol. Antioxid Redox Signal 3, 1041-1064.
13. Gao X, Xu YX, Divine G, et al. (2002) Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes. J Nutr 132, 2076-2081.
14. Das DK, Sato M, Ray PS, et al. (1999) Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs Exp Clin Res 25, 115-120.
15. Frankel EN, Waterhouse AL & Kinsella JE (1993) Inhibition of human LDL oxidation by resveratrol. Lancet 341, 1103-1104.
16. Pace-Asciak CR, Hahn S, Diamandis EP, et al. (1995) The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235, 207-219.
17. Fontecave M, Lepoivre M, Elleingand E, et al. (1998) Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Letters 421, 277-279.
18. Chun YJ, Kim MY & Guengerich FP (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 262, 20-24.
19. Stern MP (1995) Diabetes and cardiovascular disease. The 'common soil' hypothesis. Diabetes 44, 369-374.
20. Yudkin JS (2003) Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 27, Suppl. 3, S25.
21. Hotamisligil GS (2003) Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27, Suppl. 3, S53.
22. Penumathsa SV, Koneru S, Samuel SM, et al. (2008) Strategic targets to induce neovascularization by resveratrol in hypercholesterolemic rat myocardium: role of caveolin-1, endothelial nitric oxide synthase, hemoxygenase-1, and vascular endothelial growth factor. Free Radic Biol Med 45, 1027-1034.
23. De Jesus Soares T, Volpini RA, Francescato HD, et al. (2007) Effects of resveratrol on glycerol-induced renal injury. Life Sci 81, 647-656.
24. Sharma S, Anjaneyulu M, Kulkarni SK, et al. (2006) Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 76, 69-75.
25. Meng X, Maliakal P, Lu H, et al. (2004) Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 52, 935-942.
26. Wenzel E, Soldo T, Erbersdobler H, et al. (2005) Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 49, 482-494.
27. Wong YT, Gruber J, Jenner AM, et al. (2009) Elevation of oxidative damage biomarkers during aging in F2 hybrid mice: protection by chronic oral intake of resveratrol. Free Radic Biol Med 46, 799-809.
28. Bertelli A, Bertelli AA, Gozzini A, et al. (1998) Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 24, 133-138.
29. Walle T, Hsieh F, DeLegge MH, et al. (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32, 1377-1382.
30. Monks TJ & Lau SS (1998) The pharmacology and toxicology of polyphenolic glutathione conjugates. Annu Rev Pharmacol Toxicol 38, 229-255.
31. Caballero AE (2003) Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 11, 1278-1289.
32. Hwa JJ, Ghibaudi L, Williams P, et al. (1994) Comparison of acetylcholine-dependent relaxation in large and small arteries of rat mesenteric vascular bed. Am J Physiol Heart Circ Physiol 266, H952-H958.
33. Steinberg HO, Chacker H, Leaming R, et al. (1996) Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest 97, 2601-2610.
34. Anderson TJ (2003) Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 8, 71-86.
35. Hattori R, Otani H, Maulik N, et al. (2002) Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol Heart Circ Physiol 282, H1988-H1995.
36. Klinge CM, Risinger KE,Watts MB, et al. (2003) Estrogenic activity in white and red wine extracts. J Agric Food Chem 51, 1850-1857.
37. Sato M, Maulik G, Bagchi D, et al. (2000) Myocardial protection by protykin, a novel extract of trans-resveratrol and emodin. Free Radic Res 32, 135-144.
38. Lekli I, Szabo G, Juhaz B, et al. (2008) Protective mechanisms of resveratrol against ischemia-reperfusioninduced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol 294, H859-H866.
39. McCarthy MI & Hattersley AT (2001) Molecular diagnosis in monogenic and multifactoral forms of type 2 diabetes. Expert Rev Mol Diagn 1, 403-412.
40. Inoguchi T, Li P, Umeda F, et al. (2000) High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49, 1939-1945.
41. Grove J, Daly AK, Bassendine MF, et al. (1997) Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 26, 143-146.
42. Schuster DP & Duvuuri V (2002) Diabetes mellitus. Clin Podiatr Med Surg 19, 79-107.
43. Tominaga M, Eguchi H, Manaka H, et al. (1999) Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22, 920-924.
44. Lee CK, Klopp RG, Weindruch R, et al. (1999) Gene expression profile of aging and its retardation by caloric restriction. Science 285, 1390-1393.
45. Barger JL, Kayo T, Vann JM, et al. (2008) A low dose of resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 3, e2264.
46. Anderson RM, Bitterman KJ, Wood JG, et al. (2003) Nicotinamide and Pnc1 govern lifespan extension by calorie restriction in S. cerevisiae. Nature 423, 181-185.
47. Howitz KT, Bitterman KJ, Cohen HY, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196.
48. Dasgupta B & Milbrandt J (2007) Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A 104, 7217-7222.
49. Wallace DC (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 39, 359-407.
50. Lagouge M, Argman C, Gerhart-Hines Z, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1a. Cell 127, 1109-1122.
51. Petersen KF, Befroy D, Dufour S, et al. (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300, 1140-1142.
52. Virkamaki A, Korsheninnikova E, Seppala-Lindroos A, et al. (2001) Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 50, 2337-2343.
53. Patti ME, Butte AJ, Crunkhorn S, et al. (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 100, 8466-8471.
54. Petersen KF, Dufour S, Befroy D, et al. (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350, 664-671.
55. Haneke KE, Carson BL, Gregorio CA, et al. (2002) Review of Toxicological Literature for Resveratrol Prepared for Scott Masten. National Institute of Environmental Health Sciences (NIEHS). Submitted by Integrated Laboratory Systems, Inc., through NIEHS contract N01- ES-6540. Research Triangle, NC: NIEHS. http://ntp. niehs.nih.gov/ntp/htdocs/Chem-Background/ExSumPDF/ resveratrol.pdf
56. Juan ME, Vinardell MP & Planas JM (2002) The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 132, 257-260.
57. Crowell JA, Korytko PJ, Morrissey RL, et al. (2004) Resveratrol- associated renal toxicity. Toxicol Sci 82, 614-619.